FIELD: medicine.
SUBSTANCE: invention can be used for determining a functional status of primary signalling pathways of a cell. Substance of the invention are lentiviral reporter vector structures containing reporter markers. The invention allows predicting the tumour sensitivity to therapeutic exposures and developing an individual therapeutic approach.
EFFECT: creating the lentiviral reporter vector structure optimal for determining the activity of transcriptional factors reflecting the functional status of signalling pathways of the cell.
6 cl, 16 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| REPORTER SYSTEM BASED ON LENTIVIRUS REPORTER STRUCTURES FOR STUDY OF PROTEIN-PROTEIN INTERACTIONS | 2015 |
|
RU2639539C2 |
| DIAGNOSTIC TECHNIQUE FOR BREAST CANCER | 2013 |
|
RU2547583C2 |
| NON-TOXIC VECTORS ON HSV BASIS FOR APPLICATIONS IN EFFECTIVE GENE DELIVERY AND COMPLEMENTING CELLS FOR THEIR PRODUCTION | 2014 |
|
RU2714259C2 |
| METHOD OF CREATING TRANSGENE MAMMAL CELL LINES WITH STABLE AND HIGH LEVEL OF TRANSGENE PROTEIN EXPRESSION | 2009 |
|
RU2425882C1 |
| DESIGNING OF CARCINOLYTIC ADENOVIRUS RECOMBINANT, SPECIFICALLY EXPRESSING IMMUNOMODULATORY FACTOR GM-CSF IN TUMORAL CELLS AND ITS APPLICATION | 2004 |
|
RU2361611C2 |
| GENETIC CONSTRUCT FOR INDUCING PROLIFERATION OF PERIPHERAL MONOCYTES IN VITRO | 2017 |
|
RU2697797C2 |
| METHOD FOR DETERMINING ACTIVITY OF TRANSCRIPTION FACTORS | 2012 |
|
RU2520083C1 |
| DOUBLE HYBRID SYSTEM BASED ON GENE SILENCING BY TRANSCRIPTIONAL INTERFERENCE | 2005 |
|
RU2403287C2 |
| COMPOSITIONS OF HUMANISED NOTCH FUSED PROTEINS AND METHODS OF TREATING | 2008 |
|
RU2532830C2 |
| INDUCIBLE PROMOTER, VECTOR AND HOST CELL BASED THEREON | 2021 |
|
RU2820059C2 |
